Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
15(2), P. 852 - 875
Published: Nov. 23, 2024
Cancer
immunotherapy
is
currently
a
very
promising
therapeutic
strategy
for
treating
tumors.
However,
its
effectiveness
restricted
by
insufficient
antigenicity
and
an
immunosuppressive
tumor
microenvironment
(ITME).
Pyroptosis,
unique
form
of
programmed
cell
death
(PCD),
causes
cells
to
swell
rupture,
releasing
pro-inflammatory
factors
that
can
enhance
immunogenicity
remodel
the
ITME.
Nanomaterials,
with
their
distinct
advantages
different
techniques,
are
increasingly
popular,
nanomaterial-based
delivery
systems
demonstrate
significant
potential
potentiate,
enable,
augment
pyroptosis.
This
review
summarizes
discusses
emerging
field
nanomaterials-induced
pyroptosis,
focusing
on
mechanisms
pyroptosis
pathways
strategies
activate
or
specific
Additionally,
we
provide
perspectives
development
this
field,
aiming
accelerate
further
clinical
transition.
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: May 7, 2024
Abstract
The
development
of
intelligent,
environmentally
responsive,
and
biocompatible
photothermal
system
holds
significant
importance
for
the
combined
therapy
tumors.
In
this
study,
inspired
by
lactobacillus,
we
prepared
a
biomimetic
nanoplatform,
PDA&DOX@LAC,
tumor
photothermal-chemotherapy
integrating
chemotherapeutic
drug
doxorubicin
(DOX)
with
dopamine
through
oxidative
polymerization
to
form
polydopamine
on
surface
LAC.
PDA&DOX@LAC
nanoplatform
not
only
achieves
precise
controlled
release
DOX
based
slightly
acidic
microenvironment
tissues,
but
also
exhibits
enzyme-like
properties
alleviate
hypoxia.
Under
near-infrared
light
irradiation,
it
effectively
induces
ablation
cells,
enhances
cellular
uptake
increasing
temperature,
thus
efficiently
inhibits
cell
growth.
Moreover,
in
vivo
experiments
further
confirmed
that
cells
apoptosis,
releases
tumor-associated
antigens,
is
engulfed
dendritic
activating
cytotoxic
T
lymphocytes,
thereby
suppressing
growth
prolonging
survival
period
4T1
tumor-bearing
mice.
Therefore,
immense
potential
in
targeting
therapy,
providing
valuable
insights
theoretical
foundations
novel
treatment
strategies
endogenous
substances
within
body.
Clinical and Experimental Medicine,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: Sept. 26, 2024
The
escalating
incidence
of
breast
cancer
(BC)
in
women
underscores
its
grave
health
threat.
Current
molecular
insights
into
BC's
post-adjuvant
therapy
cure
remain
elusive,
necessitating
active
treatment
explorations.
Immunotherapy,
notably
chemotherapy-induced
immunogenic
cell
death
(ICD),
has
emerged
as
a
promising
BC
therapy.
ICD
harnesses
chemotherapeutics
to
activate
anti-tumor
immunity
via
DAMPs,
fostering
long-term
T-cell
memory
and
primary
cure.
Besides
chemotherapy
drugs,
Nanodrugs,
traditional
Chinese
medicine
(TCM)
ICIs
also
induce
ICD,
boosting
immune
response.
ICIs,
like
PD-1/PD-L1
inhibitors,
revolutionize
but
face
limited
success
cold
tumors.
Thus,
induction
combined
with
is
studied
extensively
for
immunotherapy.
This
article
reviews
the
mechanism
related
drugs
provides
reference
research
development
treatment,
order
explore
more
effective
clinical
BC,
we
hope
inducers
make
vaccines.
Acta Pharmaceutica Sinica B,
Journal Year:
2024,
Volume and Issue:
15(2), P. 852 - 875
Published: Nov. 23, 2024
Cancer
immunotherapy
is
currently
a
very
promising
therapeutic
strategy
for
treating
tumors.
However,
its
effectiveness
restricted
by
insufficient
antigenicity
and
an
immunosuppressive
tumor
microenvironment
(ITME).
Pyroptosis,
unique
form
of
programmed
cell
death
(PCD),
causes
cells
to
swell
rupture,
releasing
pro-inflammatory
factors
that
can
enhance
immunogenicity
remodel
the
ITME.
Nanomaterials,
with
their
distinct
advantages
different
techniques,
are
increasingly
popular,
nanomaterial-based
delivery
systems
demonstrate
significant
potential
potentiate,
enable,
augment
pyroptosis.
This
review
summarizes
discusses
emerging
field
nanomaterials-induced
pyroptosis,
focusing
on
mechanisms
pyroptosis
pathways
strategies
activate
or
specific
Additionally,
we
provide
perspectives
development
this
field,
aiming
accelerate
further
clinical
transition.
